Impulse Pharma

Impulse Pharmaceuticals is a clinical-stage biotechnology company focused on developing transformative treatments for central nervous system (CNS) disorders. Headquartered in Hangzhou, China, the company utilizes a proprietary translational medicine platform to identify and validate novel therapeutic targets, particularly G-protein coupled receptors (GPCRs). Its lead candidate, IMR-261, is a small molecule GPR139 agonist currently in Phase 2 clinical trials for the treatment of Parkinson's disease. The company's pipeline also includes programs for restless legs syndrome and other neuropsychiatric conditions. Impulse is supported by a strong syndicate of investors, including IDG Capital, Eight Roads Ventures, and F-Prime Capital. By bridging the gap between laboratory discovery and clinical application, Impulse Pharmaceuticals aims to address significant unmet needs in global mental and neurological health.